Li Zhang, Ph.D., represents clients in the biotechnology and pharmaceutical areas. With a doctorate in cell biology and a federal district court clerkship, he advises clients in patent litigation, strategic counseling, patent prosecution, and post-grant proceedings before the U.S. Patent and Trademark Office (USPTO).
Li focuses on patent litigation. His practice includes Biologics Price Competition and Innovation Act (BPCIA) and Abbreviated New Drug Application (ANDA) litigation, and post-grant proceedings (e.g., post-grant review (PGR), inter partes review (IPR)) before the USPTO's Patent Trial and Appeal Board (PTAB). Prior to joining Finnegan, Li clerked for Judge Leonard P. Stark in the U.S. District Court for the District of Delaware, where he assisted the court in managing one of the nations busiest patent dockets.
Li's practice includes patent prosecution, strategic client counseling, and portfolio development. He has conducted research in cellular and molecular biology and co-authored more than a dozen peer-reviewed publications in scientific journals. Li is well-versed in technologies across the life science fields and has assisted clients in patent prosecution, strategic counseling, and freedom-to-operate analysis on subject matters including antibodies, antibody-drug conjugates, gene editing (e.g., CRISPR), gene therapy, modified polynucleotides, and compound biosynthesis.
D. Mass. Patent Litigation Update: February 2023 D. Mass. Patent Litigation Update: February 2023
March 14, 2023
Federal Circuit IP Blog
Federal Circuit Adopts Amendments to Federal Circuit Rules of Practice Federal Circuit Adopts Amendments to Federal Circuit Rules of Practice
March 3, 2023
D. Mass. Patent Litigation Update: January 2023 D. Mass. Patent Litigation Update: January 2023
February 23, 2023
D. Mass. Patent Litigation Update: December 2022 D. Mass. Patent Litigation Update: December 2022
January 23, 2023
The Finnegan UPC Hub is a one-stop shop for our insights related to the Unified Patent Court (UPC).